ASND Stock — Ascendis Pharma A/S

Ascendis Pharma A/S (ASND)

Updated October 16, 2026.

ASND is a Stock. Total return is 1096.2% over the past 11.7 years, 733.4 points ahead of SPY at 362.8%.

Ascendis Pharma A/S is a biopharmaceutical company developing TransCon-based therapies for rare endocrine diseases and oncology conditions, with marketed products including SKYTROFA for pediatric growth hormone deficiency and YORVIPATH for chronic hypoparathyroidism, alongside a pipeline of clinical-stage candidates. The company does not currently have an established distribution schedule. This security may appeal to investors seeking exposure to specialty pharmaceutical development with a focus on rare disease treatment.

ASND performance versus SPY

Price and return data through 2026-10-16.

Total return is 1096.2% over the past 11.7 years, 733.4 points ahead of SPY at 362.8%. Over the past year its total return — price change plus distributions reinvested — is 8.8%. Its deepest 1-year drawdown was 19.7%.

ASND key facts

Asset type

Stock

Asset class

Equity

Inception date

01/28/2015

Distribution frequency

None

Last close

$225.25 (as of 2026-10-16)

Market cap

$14,822,270,360

Average volume

680312.0

Beta

0.485

Payout ratio

0.0%

P/E ratio

17.26

Forward P/E

19.8413

EPS

$13.05

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ASND risks and drawbacks

The deepest 1-year drawdown on record here is 19.7%.

Who may consider ASND — and who may not

It is a weaker fit for investors who need monthly cash flow (ASND does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on ASND

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions